Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

STRATA Skin Sciences (SSKN) EBITDA (2016 - 2025)

STRATA Skin Sciences (SSKN) has disclosed EBITDA for 14 consecutive years, with $488000.0 as the latest value for Q4 2025.

  • Quarterly EBITDA rose 111.39% to $488000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$4.7 million through Dec 2025, up 49.22% year-over-year, with the annual reading at -$4.7 million for FY2025, 49.22% up from the prior year.
  • EBITDA hit $488000.0 in Q4 2025 for STRATA Skin Sciences, up from -$1.2 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $488000.0 in Q4 2025 to a low of -$4.3 million in Q4 2024.
  • Historically, EBITDA has averaged -$1.6 million across 5 years, with a median of -$1.6 million in 2022.
  • Biggest five-year swings in EBITDA: surged 121.54% in 2022 and later tumbled 2667.91% in 2023.
  • Year by year, EBITDA stood at -$622000.0 in 2021, then surged by 121.54% to $134000.0 in 2022, then crashed by 2667.91% to -$3.4 million in 2023, then dropped by 24.53% to -$4.3 million in 2024, then skyrocketed by 111.39% to $488000.0 in 2025.
  • Business Quant data shows EBITDA for SSKN at $488000.0 in Q4 2025, -$1.2 million in Q3 2025, and -$2.3 million in Q2 2025.